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Objective: We assessed the outcomes of intravenous thrombolysis (IVT) in acute 
ischemic stroke (AIS) patients on dual antiplatelet therapy prior to stroke onset.  
Methods: We analyzed prospectively collected data from the SITS International 
Stroke Thrombolysis Register (SITS-ISTR) on consecutive IVT-treated AIS patients 
during a seven-year period (2010-2017). In propensity-score matched groups of 
patients with dual antiplatelet pretreatment and no antiplatelet pretreatment we 
compared: 1) SICH, according to SITS-MOST, ECASS II and NINDS definitions, 2) 
3-month mortality, 3) 3-month favorable functional outcome (FFO; mRS-scores:0-1), 
4) 3-month functional independence (FI; mRS-scores:0-2) and 5) distribution of the 3-
month mRS-scores. Dual antiplatelet pretreatment was defined as all possible 
combinations among aspirin, clopidogrel, dipyridamole or any other antiplatelet. 
Results: Propensity-score matching resulted in two groups of 1043 patients each, 
balanced for all baseline characteristics. In the propensity-score matched analysis the 
two groups had comparable (p>0.017 using Bonferroni correction for multiple 
comparisons) SICH rates according to SITS-MOST (2.9% vs. 1.5%; 95%CI:-0.03,-
0.01), ECASS II (5.2% vs. 4.4%; 95%CI:-0.03,0.01) and NINDS (7.7% vs. 6.6%; 
95%CI:-0.03,0.01) definitions. No differences in the 3-month mortality (17.9% vs. 
16.6%; 95%CI:-0.05,0.02), FFO (45.6% vs. 46.0%; 95%CI:-0.04,0.05), FI rates 
(59.2% vs. 60.7%; 95%CI:-0.03,0.06) or the distribution in 3-month mRS-scores [2 
(1-4) vs. 2 (0-4); 95%CI:-0.29,0.09] were documented between the two groups. 
Interpretation: Given that patients on dual antiplatelet pretreatment have similar 
SICH, 3-month mortality rates and functional outcomes compared to patients with no 
antiplatelet pretreatment, dual antiplatelet pretreatment history should not be used as a 
reason to withhold IVT in otherwise eligible AIS patients. 












Even though, antiplatelet pretreatment is not considered a contraindication for 
intravenous thrombolysis (IVT) with tissue plasminogen activator (tPA) in eligible 
acute ischemic stroke (AIS) patients,
1
 there are contradictory data regarding the 
association of antiplatelet pretreatment with safety and efficacy outcomes of AIS 
patients treated with systemic thrombolysis.
2
  
 A systematic review and meta‐analysis of 19 observational studies on the 
safety and efficacy of IVT for AIS in patients receiving antiplatelet therapy prior to 
stroke onset reported higher odds of post-thrombolytic symptomatic intracerebral 
haemorrhage (SICH) in AIS patients receiving dual antiplatelet pretreatment, with 
combination of acetylsalicylic acid (ASA) and clopidogrel, when compared to 
patients without history of dual antiplatelet pretreatment intake (OR=1.88, 95% CI 
1.18–3.00).
3
 However, all included studies in the aforementioned meta-analysis were 
retrospective with patients taking long-term antiplatelet medications being 
significantly older and with more comorbidities.
3
 Moreover, a recent pre-specified 
subgroup analysis of Enhanced Control of Hypertension and Thrombolysis Stroke 
Study (ENCHANTED) has reported that antiplatelet adversely affects safety and 
efficacy outcomes of IVT for AIS.
4
 Finally, a post-hoc analysis of the Virtual 
International Stroke Trials archives reported discouraging results with IVT compared 
to placebo in a small subgroup of AIS patients with dual antiplatelet pretreatment 
history.
5
 Notably, the rate of SICH per ECASS II definition was the highest (8.5%) in 
this specific subgroup in comparison to all other AIS subgroups treated with alteplase 
despite contraindications and warnings.
5
 










In view of the former considerations we sought to assess the impact of dual 
antiplatelet pretreatment on the safety and efficacy outcomes of AIS patients treated 
with IVT by analysing propensity score matched data from the Safe Implementation 
of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). 
 
Methods 
We analyzed prospectively collected data from the SITS-ISTR on consecutive 
AIS patients treated with IVT from January 1, 2010 to June 15, 2017. SITS-ISTR data 
were collected from participating centers treating AIS patients with IVT using the 
general register platform, as previously described.
6,7
 
We included all AIS patients treated with tPA if they had: 1. available data 
regarding the history of antiplatelet intake prior to stroke onset 2. no significant 
disability prior to stroke onset (modified Rankin Scale score, mRS ≤1) 3. available 3-
month functional outcome assessment using the mRS-score, 4. available follow-up 
neuroimaging with either computed tomography or magnetic resonance imaging after 
IVT administration. Patients with history of single antiplatelet intake were excluded 
from the present analysis since our aim was to compare safety and efficacy outcomes 
of IVT in AIS patients pretreated with dual antiplatelet in comparison to AIS without 
antiplatelet pretreatment. Dual antiplatelet pretreated patients had received at least any 
of the combinations of ASA, clopidogrel, dipyridamole or other antiplatelet.  
After dichotomization according to the history of dual antiplatelet intake prior 
to stroke onset, patients in the treatment group (patients with history of dual 
antiplatelet pretreatment) were matched to control group patients without any prior 
antiplatelet treatment at stroke onset. For matching we used a structured, iterative 
propensity score model with inclusion of all baseline characteristics, except for the 










history of dual antiplatelet pretreatment, and the primary objective to maximize the 
balance in the distribution of possible confounders between the two aforementioned 
groups.
8,9
 The corresponding propensity score of the treatment variable (history of 
dual antiplatelet intake) was calculated for each subject and a nearest neighbor 
matching algorithm with a 1:1 allocation was subsequently implemented to match 
eligible patients in the treatment group (patients with history of dual antiplatelet 
preatreatment) to patients in the control group (patients without history of antiplatelet 
pretreatment). To determine whether the propensity score matching approach 
achieved balance in all potential confounders, we compared all baseline 
characteristics of patients in the treatment group to their control patients, before and 
after propensity score matching.
10
 
In the propensity score matched groups we assessed the following safety 
outcome events of interest: 1. SICH rates according to the SITS-MOST definition 
[local or remote parenchymatous hemorrhage type 2 within 22–36 hours imaging 
scans combined with ≥4 points worsening on the National Institutes of Health Stroke 
Scale (NIHSS) score or leading to death within 24 hours],
11
 ECASS II definition (any 
intracranial bleed with ≥4 points worsening on the NIHSS score)
12
 and NINDS 
definition (any intracranial bleed with ≥1 point worsening on the NIHSS score),
13
 2. 
symptomatic remote parenchymal hemorrhage, defined as solitary or multiple 
hemorrhages appearing in brain regions without visible ischemic damage, remote 
from the area of ischemia causing the initial stroke symptoms, accompanied with 
early neurological deterioration as previously described.
14
 3. asymptomatic 
intracranial hemorrhage (aICH) defined as evidence of intracranial bleeding on brain 
CT without neurological worsening using NINDS definition (≥1 point increase in the 
NIHSS-score) 4. mortality rates at 3 months. 










We also evaluated the following efficacy outcome events of interest: 1. 
favorable functional outcome (FFO) at 3 months rates (defined as mRS-score of 0 or 
1),
10
 2. functional independence (FI) at 3 months rates (defined as mRS-score 0-2)
10
 
and 3. functional improvement at the months quantified by the distribution of 3-month 
mRS-scores between the two groups.
15 
Finally, we performed subgroup analyses for 
all safety and efficacy outcomes between patients receiving dual antiplatelet 
pretreatment with the combination of ASA and clopidogrel and patients receiving 
dual antiplatelet pretreatment with other antiplatelet combinations or patients 




Statistical comparisons between the aforementioned propensity score matched 
groups were performed s using the χ2-test (or the Fisher’s exact test) and the unpaired 
t-test (or Mann-Whitney U-test), where appropriate, while the distribution of the 
mRS-scores at three months in propensity score matched dual antiplatelet 
pretreatment and no antiplatelet pretreatment groups was compared using the 
Cochran-Mantel-Haenszel test.
14
 The differences in all clinical outcomes of interest 
between the two groups were tested under statistical significance hypotheses using an alpha 
value of 0.05. To avoid false positive findings due to multiple testing in the primary 
safety outcome of SICH, being assessed with three different definitions, we 
implemented a more conservative significance threshold of 0.05/3=0.017, using the 
Bonferroni correction for multiple testing. Statistical analyses were performed with 
RStudio: A Language and Environment for Statistical Computing (R Foundation for 
Statistical Computing, Vienna, Austria), with the use of the “MatchIt” package 










(Matching software for causal inference) for matching patients across the two 
groups,
16




Out of a total 95,923 IVT-treated AIS patients we identified 28,112 eligible 
patients (Figure 1). The two groups had only comparable baseline stroke severity 
(Table 1), while patients with dual antiplatelet pretreatment (n=1,355) were older 
(95%CI: -6.00, -4.80; p<0.001) and had higher prevalence of all vascular risk factors 
(p<0.001), except for the history of current smoking, compared to patients without 
antiplatelet pretreatment history (n=26,757). Dual antiplatelet pretreated patients had 
also higher rates of statin pretreatment (95%CI: -0.59, -0.54; p<0.001), lower systolic 
(95%CI: 0.73, 3.27; p=0.002) and diastolic blood pressure (95%CI: 2.63, 4.16; 
p<0.001) on admission, higher baseline glucose levels (95%CI: -6.28, -0.52; 
p=0.023), shorter onset-to-treatment times (95%CI: 1.81, 7.99; p<0.001) and less 
endovascular reperfusion therapies (95%CI: 0.01, 0.03; p=0.004) following alteplase 
infusion compared to patients without antiplatelet pretreatment history (Table 1).  
Propensity score matching resulted in two groups of 1043 patients each 
(Figure 2), balanced for all baseline characteristics (Table 2). Dual antiplatelet 
pretreated patients had received combinations of ASA with clopidogrel (n=617) or 
dipyridamole (n=324) or other antiplatelet (n=87), combinations of clopidogrel with 
dipyridamole (n=3) or other antiplatelet (n=11) and combination of dipyridamole with 
other antiplatelet (n=1). In propensity score matched analysis patients with dual 
antiplatelet pretreatment history had comparable SICH rates, according to the SITS-
MOST (2.9% vs. 1.5%; 95%CI: -0.03, -0.01; p=0.037 - considered non-significant 










taking into account the threshold of 0.017 due to Bonferroni adjustment), ECASS II; 
p=0.354) and NINDS definitions (7.7% vs. 6.6%; 95%CI: -0.03, 0.01; p=0.318), to 
patients with no antiplatelet pretreatment history. The two groups did not differ in 
terms of symptomatic remote parenchymal hemorrhage (1.1% vs. 0.6%; 95%CI: -0.01, 
0.01; p=0.155) and aICH (6.9% vs. 6.2%; 95%CI: -0.03, 0.01; p=0.526). 
Additionally, no differences in the 3-month mortality (17.9% vs. 16.6%; 95%CI: -
0.05, 0.02; p=0.417), FFO (45.6% vs. 46.0%; 95%CI: -0.04, 0.05; p=0.860) and FI 
rates (59.2% vs. 60.7%; 95%CI: -0.03, 0.06; p=0.503) were detected between the two 
groups (Table 3), while the distribution of the 3-month mRS-scores was comparable 
[2 (1-4) vs. 2 (0-4); 95%CI: -0.29, 0.09; p=0.683; Figure 3].  
Subgroup analyses revealed no disparities in the outcomes of interest between 
patients receiving pretreatment with the combination of ASA and clopidogrel (n=617) 
and patients with history of pretreatment with other antiplatelet combinations (n=426; 
Figure 4A) or combination of ASA and dipyridamole (n=324; Figure 4B).  
 
Discussion 
Our study showed that dual antiplatelet pretreatment was not associated with higher risk 
of SICH, remote SICH and asymptomatic ICH in AIS patients treated with IVT. Likewise, 3-
month mortality and functional outcomes were not affected by dual antiplatelet intake prior to 
stroke onset. Our findings are in accordance and provide further support to the recently 
published guidelines from the American Heart Association/ American Stroke 
Association recommending that the benefit of IVT treatment for eligible AIS patients 
with history of dual antiplatelet intake outweighs the probability of increased SICH 
risk (Class I; Level of Evidence B).
17
 










An increased risk of SICH per SITS-MOST in patients with dual antiplatelet 
pretreatment history receiving IVT has previously been reported in a SITS-ISTR 
analysis of 31,627 patients during an eight year period (2002-2010), highlighting dual 
antiplatelet pretreatment history as the strongest predictor of SICH (according to the 
SITS-MOST definition).
18
 Likewise, in another analysis from the SITS-ISTR registry 
that evaluated 11,865 AIS patients receiving IVT treatment during a 5-year period 
(2002-2007) the combination of ASA and clopidogrel was independently associated 
with an increased risk for SICH per NINDS and ECASS II definitions. However, no 
significant differences were found on the functional recovery and 3-months mortality 




Compared to the aforementioned reports from the SITS-ISTR, including only 
patients between 18 and 80 years of age receiving IVT treatment within the 3-hour 
time window,
18,19
 the current study provides additional data on the impact of dual 
antiplatelet pretreatment in post-IVT outcomes by incorporating data from AIS 
patients over 80 years old (19.1%), receiving IVT treatment beyond 3 hours (28.9%) 
or treated with concomitant endovascular reperfusion therapies after IVT 
administration (3.3%). Finally, it should be noted that in the present analysis we 
included a significantly higher number of dual antiplatelet pretreated patients 
compared to both the VISTA archive (n=71)
5
 and the previous SITS-ISTR report 
(n=326).
19
 We have also implemented a propensity score matching algorithm that 
balanced the two groups for all available baseline characteristics, since patients with 
dual antiplatelet pretreatment history have a higher prevalence of vascular 
comorbidities (coronary artery disease, peripheral arterial disease, prior ischemic 
stroke) compared to patients without antiplatelet pretreatment. 










Our findings further challenge the recent pre-specified subgroup analysis of 
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) 
suggesting that the history of antiplatelet pretreatment adversely affects safety and 
efficacy outcomes of IVT for AIS,
20
 highlighting further the confounding role of 
increasing age and co-existing vascular comorbidities that are more prevalent in AIS 
patients pretreated with antiplatelets.
20
 These findings are also in line with a recent 
meta-analysis highlighting that pretreatment with single or dual antiplatelet therapies 
was not associated with a higher risk of SICH and worse 3-month functional 




Several limitations of the present report need to be acknowledged. First, this is 
an observational study design with retrospective analysis of prospectively collected 
data and therefore selection bias cannot be excluded. Second, despite the fact that all 
our analyses were performed in propensity score matched groups that were balanced 
for all available baseline characteristics, the presence of potential imbalances in 
unmeasured confounders (e.g. neuroimaging parameters, cerebral microbleed 
presence prior to IVT administration) cannot be excluded. Third, SITS-ISTR is an 
observational multinational registry with self-reported safety and effectiveness 
outcomes and no central adjudication of imaging or clinical outcomes. Even though 
significant heterogeneity in acute stroke care may be present across different national 
systems and also within institutions from the same country, the SITS-ISTR reflects 
‘real-life’ clinical experience from several countries and thus we consider our results 
to be independent from particular healthcare system features and thus directly 
generalizable. Fourth, missing data in SITS-ISTR may introduce another source of 
bias.
6
 The differences in the SICH rates of AIS patients with and without dual 










antiplatelet pretreatment history that were documented both in the current and 
previous SITS-ISTR analysis
19
 reached different levels of statistical significance 
according to the varying SICH definitions. This disparity may be attributed not only 
to the inherent heterogeneity of available SICH definitions, but also to missing data 
for SICH-ECASS II (1.4% of study population) and SICH-NINDS (1.1% of study 
population) outcomes in the current analysis. Taking also into account the vast 
differences across the two groups (Table 1) and the large number of treated 
individuals, we performed a 1:1 nearest neighbor matching, considering that an 
increased matching ratio will not result in significant improvement of the overall 
precision and may increase the risk of bias due to the lower quality of the second 
matches compared to the first ones.
22
 Finally, it should be noted that no information on the 
clinical indication or the duration of dual antiplatelet pretreatment were available and thus 
additional analyses evaluating the effect of clinical indication and dual antiplatelet treatment 
duration on safety and efficacy outcomes were not feasible.  
In conclusion, our study provides reassurance to stroke clinicians that patients on dual 
antiplatelet therapies prior to index stroke onset have comparable 3-month survival and 
functional outcomes compared to patients without history of any antiplatelet intake. History 
of dual antiplatelet pretreatment should not be used as a sole reason to withhold IVT in 
otherwise eligible AIS patients. 
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Figure legends  
 
Figure 1. Flowchart presenting the selection of eligible and propensity score matched 
patients. 
 
Figure 2. Distribution of propensity scores between acute ischemic stroke patients 
with and without history of dual antiplatelet therapy before and after propensity score 
matching. 
 
Figure 3. Distribution of the modified Rankin Scale scores at three months between 
acute ischemic stroke patients with and without history of dual antiplatelet therapy 
prior to the administration of intravenous thrombolysis. 
 
Figure 4. Subgroup analyses on the safety and efficacy outcomes between patients 
receiving pretreatment with combination of acetylsalicylic acid and clopidogrel 
compared to (A) patients receiving pretreatment with other antiplatelet combinations 
and (B) patients receiving pretreatment with combination of acetylsalicylic acid and 
dipyridamole. 
 



























Age (mean±SD), years 71.6±10.8 66.2±13.8 -6.00, -4.80 <0.001 
Males (%) 68.2% 56.1% -0.15, -0.10 <0.001 
Admission NIHSS (median, IQR) 9 (6-16) 9 (6-15) -0.34, 0.34 0.918 
Hypertension (%) 81.1% 56.6% -0.27, -0.22 <0.001 
Diabetes (%) 28.8% 14.2% -0.17, -0.12 <0.001 
Hyperlipidemia (%) 57.5% 21.3% -0.39, -0.33 <0.001 
Current smoking (%) 15.2% 21.1% 0.04, 0.08 <0.001 
Atrial fibrillation (%) 18.8% 12.3% -0.09, -0.04 <0.001 
Congestive heart failure (%) 15.6% 4.2% -0.13, -0.09 <0.001 
History of previous stroke* (%) 30.1% 3.7% -0.29, -0.24 <0.001 
Statin pretreatment (%) 71.2% 14.7% -0.59, -0.54 <0.001 
Admission SBP baseline (mean±SD), mmHg 150.5±23.3 152.5±23.8 0.73, 3.27 0.002 
Admission DBP (mean±SD), mmHg 80.5±14.0 83.9±14.4 2.63, 4.16 <0.001 
Admission serum glucose (mean±SD), mg/dL 133.4±52.9 130.0±49.2 -6.28,-0.52 0.023 
Onset-to-treatment time (mean±SD), min 153.5±56.6 158.4±56.3 1.81, 7.99 0.002 
Endovascular reperfusion therapies (%) 3.1% 4.8% 0.01, 0.03 0.004 
 
DAPP: dual antiplatelet pretreatment, AP-: No antiplatelet pretreatment, 95%CI: 95% 
confidence intervals for the differences between the two groups, NIHSS: National 
Institutes of Health Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, IQR: interquartile range 
*earlier than 3 months before the index event 










Table 2. Baseline characteristics of propensity score matched groups 





Age (mean±SD), years 71.4±11.0 71.4±10.7 -0.93, 0.93 0.956 
Males (%) 68.4% 67.9% -0.04, 0.03 0.814 
Admission NIHSS (median, IQR) 9 (6-15) 9 (6-15) -0.57, 0.49 0.894 
Hypertension (%) 81.3% 81.4% -0.03, 0.03 0.963 
Diabetes (%) 30.1% 31.0% -0.03, 0.05 0.669 
Hyperlipidemia (%) 57.4% 59.5% -0.02, 0.06 0.334 
Current smoking (%) 15.2% 14.9% -0.03, 0.03 0.893 
Atrial fibrillation (%) 20.6% 23.3% -0.01, 0.06 0.135 
Congestive heart failure (%) 14.9% 16.8% -0.01, 0.05 0.223 
History of previous stroke* (%) 29.7% 26.7% -0.07, 0.01 0.134 
Statin pretreatment (%) 71.3% 72.8% -0.02, 0.05 0.451 
Admission SBP baseline (mean±SD), mmHg 151.2±23.4 151.0±22.7 -2.18, 1.78 0.855 
Admission DBP (mean±SD), mmHg 80.6±13.9 80.8±14.6 -1.02, 1.42 0.725 
Admission serum glucose (mean±SD), mg/dL 134±53 135±49 -3.38, 5.38 0.667 
Onset-to-treatment time (mean±SD), min 154±57 154±56 -4.85, 4.85 0.763 
Endovascular reperfusion therapies (%) 3.0% 3.5% -0.01, 0.02 0.459 
 
DAPP: dual antiplatelet pretreatment, AP-: No antiplatelet pretreatment, 95%CI: 95% 
confidence intervals for the differences between the two groups, NIHSS: National 
Institutes of Health Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, IQR: interquartile range 
 
*earlier than 3 months before the index event 










Table 3. Outcomes of propensity score matched groups. 
Variable DAPP+ AP- 95%CI p-value 
SICH (%) – SITS MOST 2.9% 1.5% -0.03, -0.01 0.037 
SICH (%) – ECASS II 5.2% 4.4% -0.03, 0.01  0.354 
SICH (%) – NINDS 7.7% 6.6% -0.03, 0.01 0.318 
Symptomatic Remote Parenchymal 
Hemorrhage (%) 
1.1% 0.6% -0.01, 0.01 0.155 
Asymptomatic Intracranial Hemorrhage (%)* 6.9% 6.2% -0.03, 0.01 0.526 
mRS at 3 months (median, IQR) 2 (1-4) 2 (0-4) -0.29, 0.09 0.683** 
FFO (mRS: 0-1) at 3 months (%) 45.6% 46.0% -0.04, 0.05 0.860 
FI (mRS: 0-2) at 3 months (%) 59.2% 60.7% -0.03, 0.06 0.503 
Mortality at 3 months (%) 17.9% 16.6% -0.05, 0.02 0.417 
DAPP: dual antiplatelet pretreatment, AP-: No antiplatelet pretreatment, 95%CI: 95% 
confidence intervals for the differences between the two groups, SICH: symptomatic 
intracerebral hemorrhage, mRS: modified Rankin Scale, FFO: favorable functional 
outcome, FI: functional independence 
 
* according to NINDS criteria 
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